These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 37823034)

  • 1. A randomized crossover study to evaluate local tolerability following subcutaneous administration of a new depot medroxyprogesterone acetate contraceptive formulation.
    Halpern V; Wheeless A; Brache V; Lendvay A; Cochón L; Taylor D; Dorflinger LJ
    Contracept X; 2023; 5():100100. PubMed ID: 37823034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ovulation suppression following subcutaneous administration of depot medroxyprogesterone acetate.
    Taylor DJ; Halpern V; Brache V; Bahamondes L; Jensen JT; Dorflinger LJ
    Contracept X; 2022; 4():100073. PubMed ID: 35281554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of ovulation and pharmacokinetics following subcutaneous administration of various doses of Depo-Provera®: a randomized trial.
    Halpern V; Fuchs R; Brache V; Bahamondes L; Miranda MJ; Lendvay A; Cochón L; Taylor D; Dorflinger LJ
    Contracept X; 2021; 3():100070. PubMed ID: 34746745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical trial to evaluate pharmacokinetics and pharmacodynamics of medroxyprogesterone acetate after subcutaneous administration of Depo-Provera.
    Halpern V; Brache V; Taylor D; Lendvay A; Cochón L; Jensen JT; Dorflinger LJ
    Fertil Steril; 2021 Apr; 115(4):1035-1043. PubMed ID: 33485608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of subcutaneous depot medroxyprogesterone acetate injected in the upper arm.
    Halpern V; Combes SL; Dorflinger LJ; Weiner DH; Archer DF
    Contraception; 2014 Jan; 89(1):31-5. PubMed ID: 23993431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Forearm bone density in users of Depo-Provera as a contraceptive method.
    Bahamondes L; Perrotti M; Castro S; Faúndes D; Petta C; Bedone A
    Fertil Steril; 1999 May; 71(5):849-52. PubMed ID: 10231044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic study of different doses of Depo Provera.
    Fotherby K; Koetsawang S; Mathrubutham M
    Contraception; 1980 Nov; 22(5):527-36. PubMed ID: 6451351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative study of one-year weight gain among users of medroxyprogesterone acetate, levonorgestrel implants, and oral contraceptives.
    Moore LL; Valuck R; McDougall C; Fink W
    Contraception; 1995 Oct; 52(4):215-9. PubMed ID: 8605778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Timing of onset of contraceptive effectiveness in Depo-Provera users: Part I. Changes in cervical mucus.
    Petta CA; Faundes A; Dunson TR; Ramos M; DeLucio M; Faundes D; Bahamondes L
    Fertil Steril; 1998 Feb; 69(2):252-7. PubMed ID: 9496338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Depot medroxyprogesterone acetate pioneers. A retrospective study at a North Carolina Health Department.
    Potter LS; Dalberth BT; Cañamar R; Betz M
    Contraception; 1997 Nov; 56(5):305-12. PubMed ID: 9437559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic parameter, bleeding, and weight changes in U.S. women using progestin only contraceptives.
    Mainwaring R; Hales HA; Stevenson K; Hatasaka HH; Poulson AM; Jones KP; Peterson CM
    Contraception; 1995 Mar; 51(3):149-53. PubMed ID: 7621683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Timing of onset of contraceptive effectiveness in Depo-Provera users. II. Effects on ovarian function.
    Petta CA; Faúndes A; Dunson TR; Ramos M; DeLucio M; Faúndes D; Bahamondes L
    Fertil Steril; 1998 Nov; 70(5):817-20. PubMed ID: 9806559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Depo-Provera in adolescents: effects of early second injection or prior oral contraception.
    Harel Z; Biro FM; Kollar LM
    J Adolesc Health; 1995 May; 16(5):379-84. PubMed ID: 7662688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Depo-Provera use in an Australian metropolitan practice.
    Fraser IS; Dennerstein GJ
    Med J Aust; 1994 May; 160(9):553-6. PubMed ID: 8164553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term depot medroxyprogesterone acetate (Depo-Provera) use in inner-city adolescents.
    Polaneczky M; Liblanc M
    J Adolesc Health; 1998 Aug; 23(2):81-8. PubMed ID: 9714170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective study of adolescents who choose among levonorgestrel implant (Norplant), medroxyprogesterone acetate (Depo-Provera), or the combined oral contraceptive pill as contraception.
    Cromer BA; Smith RD; Blair JM; Dwyer J; Brown RT
    Pediatrics; 1994 Nov; 94(5):687-94. PubMed ID: 7936897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of depot medroxyprogesterone acetate (DMPA) injectable contraceptive in Enugu, Nigeria.
    Hu E; Ikeako LC; Obiora-Okafor NC
    Niger J Med; 2012; 21(3):266-71. PubMed ID: 23304918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives.
    Cromer BA; Blair JM; Mahan JD; Zibners L; Naumovski Z
    J Pediatr; 1996 Nov; 129(5):671-6. PubMed ID: 8917232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Return of fertility after discontinuation of depot medroxyprogesterone acetate and intra-uterine devices in Northern Thailand.
    Pardthaisong T; Gray RH; McDaniel EB
    Lancet; 1980 Mar; 1(8167):509-12. PubMed ID: 6102234
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.